Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
Trial Details
- NCT ID
- NCT07804186
- Phase
- PHASE3
- Sponsor
- IDEAYA Biosciences
- Status
- RECRUITING
- Cancer Type
- Melanoma
- Interventions
- Darovasertib
- Crizotinib (Xalkori)
- Locations (sample)
- Scottsdale, Arizona, United States|33.50921,-111.89903
- Los Angeles, California, United States|34.05223,-118.24368
- Boston, Massachusetts, United States|42.35843,-71.05977
- Grand Rapids, Michigan, United States|42.96336,-85.66809
- New York, New York, United States|40.71427,-74.00597
Key Eligibility Criteria
- Primary Uveal Melanoma, classified as high-risk of relapse (AJCC Stage II or Stage 3)
- Completed primary local therapy (enucleation, proton beam therapy, plaque brachytherapy)
- ECOG performance status of 0 or 1
- Adequate organ function
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Melanoma Trials on Trialify →